Curetopia

Live

Rare Diseases

Curing the 10,000 rare genetic diseases. We are uniting patient groups and populations to tackle the $1T rare disease market. We're going directly to patients, turning them into research scientists, and making them the center of focus.

$CURES

SOL

Join Telegram

Market Details

SOL

The average likelihood of Clinical trial success from Phase 1 to approval is twice as high for rare diseases (17%) versus all diseases (8%).

$1 Trillion

Value of the Rare Disease Market

1 in 10

people suffer from a rare disease

95%

of the 10,000 rare diseases have no treatment option today

Project

Additional Documentation

Litepaper

There are 10,000 rare diseases with an average market size of $150M. Traditional pharma corporations are such large and complex institutions that they need a $1B+ TAMs to even begin exploring a disease. The same is true for a traditional VC backed biotech, with a single indication or platform. This makes the current market approach incapable of going after one of the thousands of $150M rare disease markets. However, these $150M markets are exactly where Curetopia shines and has a competitive moat.

Curetopia’s focus is specifically on this long tail of rare genetic diseases, which have a 2X higher rate of FDA approval. The family members of these rare disease patients are mission-driven warriors who have a high-risk tolerance and a 24/7 work ethic, doing whatever possible to help. Curetopia brings cures to market in a fraction of the time, with lower upfront costs.

Each rare disease uses the same underlying framework of data pooling, patient self-reporting, and feedback monitoring - Curetopia unifies this tooling and unique know-how to accelerate treatments. Family members are rewarded for contributing to the rare disease community, global researchers are incentivized to provide support, and capital is pooled together to afford drug development. Curetopia already has 8 biological targets qualified for their next set of drugs to bring to FDA trials.

Additional Documentation

Litepaper

Ethan Perlstein

Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new drugs in model organisms called evolutionary pharmacology.

Kristin Kantautas

Kristin Kantautas is a Cure Guide and Director of the Congenital Disorders of Glycosylation Program at Perlara. With a background in molecular genetics and glycobiology, she specializes in translating scientific discoveries into clinical therapies for rare metabolic diseases. Since 2022, she has led 10+ drug repurposing programs, advancing treatments to the clinic and building strategic partnerships.

Mathuravani Thevandavakkam

Director of the Yeast Drug Repurposing Program, pioneering therapeutic innovations for rare diseases. With expertise in synthetic biology, yeast models, & translational research, she has led ~20 repurposing pipelines since 2022, advancing candidates for patient studies. A catalyst for biotech innovation, she bridges science and patient-centered care to revolutionize treatments for underserved communities.

Shiri Zakin

As Mitochondrial Disease Program Director at Perlara, Shiri leads patient-centric drug repurposing initiatives for mitochondrial disorders. With 20+ years of experience in academia and industry advancing protein production, drug discovery, and delivery, she is dedicated to finding effective treatments, improving outcomes, and accelerating therapies that make a lasting impact on patient lives.